Proteintech, a global leader in antibody and life science solutions, announced the launch of Able AI , a unique artificial intelligence tool, now available at ptglab.com.
Finding the most suitable antibodies from the multitude of potential products is challenging. Able helps scientists find the right antibody for their research purposes, providing them with all the relevant information and scientific knowledge. Furthermore, it offers detailed guidance on product-specific testing procedures, significantly reducing the time required for planning and product selection.
Also Read: Exelixis Appoints Dana T. Aftab as EVP, Research & Development
This publication follows Proteintech’s successful launch of 3D epitope mapping earlier this year, which has opened up new possibilities for researchers to visualize antibody binding sites through experimental and AI-assisted modeling. This capability reduces speculation and trial-and-error, enabling scientists to better design experiments and develop products with greater precision.
” Able represents the next phase of our mission to empower scientists ,” said Dr. Jason Li, CEO of Proteintech. ” Building on the success of our 3D epitope mapping platform, Able delivers tailored product recommendations and experimental design support, allowing researchers to focus more on their groundbreaking discoveries. Proteintech is committed to pushing the boundaries in the world of reagents to enable better science and better service for every customer. “
Source: Businesswire